Payment overview · 2025
General Payments
$260,758.97
418 reported records · 34 companies
Healthcare provider profile · identity verified
John Leung, M.D.
Allopathic & Osteopathic Physicians|Allergy & Immunology|Clinical & Laboratory Immunology · BOSTON, MA · NPI 1447328711
Verified facts
What the public records show
CMS Open Payments records show John Leung, M.D. received $260,758.97 in general payments during 2025 across 418 reported records.
GENZYME CORPORATION accounted for 39.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 53 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Odactra, Rinvoq, Xolair.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rinvoq by this doctor in 2024.
ALK-Abello, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Odactra as an associated drug or biological on 3955 records involving 2461 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Odactra by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XOLAIR as an associated drug or biological on 5293 records involving 2861 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Xolair by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $103,359.52 | 39.6% | 52 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $82,352.08 | 31.6% | 67 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $27,683.41 | 10.6% | 54 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $26,262.16 | 10.1% | 35 | 2025 |
| Regeneron Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10,428.00 | 4.0% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $7,241.99 | 2.8% | 32 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $387.17 | 0.1% | 17 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $385.87 | 0.1% | 14 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $324.80 | 0.1% | 27 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $291.82 | 0.1% | 15 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $275.26 | 0.1% | 18 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $242.20 | 0.1% | 10 | 2025 |
| BioCryst US Sales Co., LLC | Unresolved — no canonical attribution shown | $217.69 | 0.1% | 7 | 2025 |
| Galderma Laboratories, L.P. | Unresolved — no canonical attribution shown | $180.05 | 0.1% | 13 | 2025 |
| QOL Medical, LLC | Unresolved — no canonical attribution shown | $159.53 | 0.1% | 6 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $151.47 | 0.1% | 6 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $95.39 | 0.0% | 6 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $80.75 | 0.0% | 3 | 2025 |
| GC Biopharma USA, Inc. | Unresolved — no canonical attribution shown | $66.92 | 0.0% | 3 | 2025 |
| Ferring Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $65.80 | 0.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $64.34 | 0.0% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $59.63 | 0.0% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $58.19 | 0.0% | 5 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $52.86 | 0.0% | 2 | 2025 |
| Pharming Healthcare, Inc. | Unresolved — no canonical attribution shown | $49.92 | 0.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.10 | 0.0% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $34.69 | 0.0% | 2 | 2025 |
| ALK-Abello, Inc | Unresolved — no canonical attribution shown | $28.88 | 0.0% | 1 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $24.47 | 0.0% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $19.28 | 0.0% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $18.85 | 0.0% | 1 | 2025 |
| Invivyd Inc | Unresolved — no canonical attribution shown | $17.56 | 0.0% | 1 | 2025 |
| Celltrion USA Inc. | Unresolved — no canonical attribution shown | $16.67 | 0.0% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.65 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $194,244.30 | 46 |
| Consulting Fee | $33,701.00 | 7 |
| Travel and Lodging | $23,804.92 | 49 |
| Food and Beverage | $8,989.56 | 314 |
| Education | $19.19 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc., Regeneron Pharmaceuticals, Inc. | $165,650.88 | 103 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $17,978.81 | 27 | 2025 |
Source payment records
|
|||||
| EOHILIA Normalized: eohilia |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $9,789.03 | 12 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $6,924.30 | 18 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $447.05 | 21 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $385.87 | 14 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $369.46 | 18 | 2025 |
Source payment records
|
|||||
| OPZELURA Normalized: opzelura |
Drug | Incyte Corporation | $291.82 | 15 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $280.42 | 25 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $275.26 | 18 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $245.32 | 8 | 2025 |
Source payment records
|
|||||
| ORLADEYO Normalized: orladeyo |
Drug | BioCryst US Sales Co., LLC | $217.69 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $184.46 | 8 | 2025 |
Source payment records
|
|||||
| NEMLUVIO Normalized: nemluvio |
Drug | Galderma Laboratories, L.P. | $180.05 | 13 | 2025 |
Source payment records
|
|||||
| Sucraid Normalized: sucraid |
Drug | QOL Medical, LLC | $159.53 | 6 | 2025 |
Source payment records
|
|||||
| CIBINQO Normalized: cibinqo |
Drug | PFIZER INC. | $135.39 | 4 | 2025 |
Source payment records
|
|||||
| ENTYVIO Normalized: entyvio |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $131.16 | 4 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $123.67 | 1 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $116.77 | 5 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $106.81 | 6 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $106.81 | 6 | 2025 |
Source payment records
|
|||||
| CUTAQUIG Normalized: cutaquig |
Biological | PFIZER INC. | $103.45 | 5 | 2025 |
Source payment records
|
|||||
| Rhapsido Normalized: rhapsido |
Drug | Novartis Pharmaceuticals Corporation | $85.13 | 5 | 2025 |
Source payment records
|
|||||
| Andembry Normalized: andembry |
Biological | CSL Behring | $83.83 | 3 | 2025 |
Source payment records
|
|||||
| AYVAKIT Normalized: ayvakit |
Biological | GENZYME CORPORATION | $82.59 | 3 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $80.75 | 3 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $67.64 | 3 | 2025 |
Source payment records
|
|||||
| ALYGLO Normalized: alyglo |
Drug | GC Biopharma USA, Inc. | $66.92 | 3 | 2025 |
Source payment records
|
|||||
| REBYOTA Normalized: rebyota |
Biological | Ferring Pharmaceuticals Inc. | $65.80 | 2 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $59.63 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $58.19 | 5 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $52.86 | 2 | 2025 |
Source payment records
|
|||||
| TAKHZYRO Normalized: takhzyro |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $51.28 | 2 | 2025 |
Source payment records
|
|||||
| OMVOH Normalized: omvoh |
Drug | Lilly USA, LLC | $50.33 | 3 | 2025 |
Source payment records
|
|||||
| RUCONEST Normalized: ruconest |
Biological | Pharming Healthcare, Inc. | $49.92 | 2 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ALK-Abello, Inc, ARS Pharmaceuticals Operations, Inc. | $48.16 | 2 | 2025 |
Source payment records
|
|||||
| CUVITRU Normalized: cuvitru |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $45.23 | 2 | 2025 |
Source payment records
|
|||||
| VTAMA Normalized: vtama |
Drug | Organon LLC | $42.26 | 3 | 2025 |
Source payment records
|
|||||
| XOLAIR Normalized: xolair |
Drug | Novartis Pharmaceuticals Corporation | $37.76 | 2 | 2025 |
Source payment records
|
|||||
| Grastek Normalized: grastek |
Drug | ALK-Abello, Inc | $28.88 | 1 | 2025 |
Source payment records
|
|||||
| Odactra Normalized: odactra |
Drug | ALK-Abello, Inc | $28.88 | 1 | 2025 |
Source payment records
|
|||||
| TRULANCE Normalized: trulance |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.85 | 1 | 2025 |
Source payment records
|
|||||
| Sajazir Normalized: sajazir |
Drug | Cycle Pharmaceuticals Inc | $24.47 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $23.23 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.53 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| PEMGARDA Normalized: pemgarda |
Biological | Invivyd Inc | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| VEGZELMA Normalized: vegzelma |
Biological | Celltrion USA Inc. | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| Livdelzi Normalized: livdelzi |
Drug | Gilead Sciences, Inc. | $12.42 | 1 | 2025 |
Source payment records
|
|||||
| HADLIMA Normalized: hadlima |
Drug | Organon LLC | $11.14 | 1 | 2025 |
Source payment records
|
|||||
| RENFLEXIS Normalized: renflexis |
Drug | Organon LLC | $11.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Odactra odactra |
2025 | Odactra | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XOLAIR xolair |
2025 | Xolair | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ALK-Abello, Inc Exact reporting entity; no affiliate inference |
2025 | Odactra open payments reported associated product |
CMS Open Payments — General Payments 3955 supporting records · 2461 recipient NPIs · example record 1222411602 |
Odactra · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | XOLAIR open payments reported associated product |
CMS Open Payments — General Payments 5293 supporting records · 2861 recipient NPIs · example record 1200005083 |
Xolair · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 56 | 17 |
| Dupixent Pen | Dupilumab | 45 | suppressed |
| Famotidine | Famotidine | 34 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 30 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 29 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 26 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Xolair | Omalizumab | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Gavilyte-G | Peg3350/Sod Sulf,bicarb,cl/Kcl | 17 | 16 |
| Mometasone Furoate | Mometasone Furoate | 17 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 17 | suppressed |
| Rinvoq | Upadacitinib | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 15 | suppressed |
| Odactra | Mite,d.Farinae-D.Pteronyssinus | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $260,758.97 · 418 records | GENZYME CORPORATION | AIRSUPRA, ALYGLO, AYVAKIT, Andembry, CIBINQO, CREON, CUTAQUIG, CUVITRU, DUPIXENT, ENTYVIO, EOHILIA, FASENRA, Fluad, Flucelvax, Grastek, HADLIMA, HYQVIA, Hizentra, IBSRELA, LINZESS, Livdelzi, NEFFY, NEMLUVIO, NUCALA, OCTAGAM IMMUNE GLOBULIN (HUMAN), OMVOH, OPZELURA, ORLADEYO, Odactra, PANZYGA, PEMGARDA, REBYOTA, RELISTOR, RENFLEXIS, REZDIFFRA, RINVOQ, RUCONEST, Rhapsido, SKYRIZI, Sajazir, Sucraid, TAKHZYRO, TEZSPIRE, TREMFYA, TRULANCE, VEGZELMA, VIBERZI, VOQUEZNA, VOWST, VTAMA, XIFAXAN, XOLAIR, Xhance | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error